Comparing the current results to its competitors, Ani Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 25.87 % year on year. The sales growth was above Ani Pharmaceuticals Inc's competitors' average revenue growth of 2.75 %, achieved in the same quarter.
Ani Pharmaceuticals Inc's Comment on Competition and Industry Peers
The company manufactures a range of pharmaceutical products, including high potency, modified release, combination, and hormonal products. It assesses market size, patient need, profit potential, and the competitive environment when deciding whether to develop or acquire products. Manufacturing is generally conducted at the company's own facilities to maintain quality control and supply chain reliability. The company analyzes existing and anticipated competition and may choose not to develop products if significant competition is expected. Its manufacturing capabilities support entry into niche markets such as hormone therapies, which typically have fewer generic competitors. The company recognizes that issued patents may be challenged or circumvented, potentially limiting proprietary protection and competitive advantages, and that competitors may independently develop similar technologies.
March 19, 2025
ANI Pharmaceuticals Unveils Nitazoxanide Tablets Amid Mixed Market Performance On March 19, 2025, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a prominent player in the pharmaceutical industry, announced the launch of Nitazoxanide Tablets, 500 mg, a significant addition to its portfolio. This product marks the company’s entry into the market for a generic version of the reference listed drug (RLD), Alinia, which is primarily utilized for the treatment of gastrointestinal infections caused by certain parasites and viruses.Nitazoxanide has been noted for its broad-spectrum antiparasitic and antiviral activity, bringing critical therapeutic options to patients who may otherwise find themselves with limited treat...
July 2, 2024
ANI Pharmaceuticals Continues Strong Market Presence with FDA Approval and Launch of New Generic Medications Princeton, N.J., July 02, 2024 - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), a leading U.S. specialty pharmaceutical company, has announced the FDA approval of its Abbreviated New Drug Application (ANDA) for Naproxen Delayed-Release Tablets, USP. The newly approved drug is the generic version of the reference listed drug (RLD) EC-Naprosyn®. This significant milestone further strengthens ANI Pharmaceuticals already robust portfolio of generic medications.The introduction of Naproxen Delayed-Release Tablets marks the third major product launch by ANI Pharmaceuticals in 2024, following the strategic la...
ANI Pharmaceuticals, a leading pharmaceutical company, has recently made a significant announcement regarding the launch of Levofloxacin Oral Solution, a generic version of the widely-used Reference Listed Drug (RLD), Levaquin. This development marks a significant milestone in the pharmaceutical industry, providing healthcare professionals and patients alike with a cost-effective alternative for the treatment of various bacterial infections.
According to IQVIA/IMS Health, a prominent healthcare data and analytics provider, Levofloxacin Oral Solution currently accounts for an estimated annual market value of approx...
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.
Collegium Pharmaceutical Inc's business model revolves around the development and commercialization of innovative products specifically designed to address the limitations of existing treatment options in pain management. They focus on developing extended-release formulations that offer abuse-deterrent properties to enhance patient safety and combat prescription drug abuse. By leveraging strategic partnerships, they aim to bring their products to market efficiently and effectively.
Sources:
Ani Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ani Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
